Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study
Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study
复制标题
DOI：
10.1089/thy.2020.0363
复制
发表时间：
2020-07-10
期刊：
影响因子：
6.6
通讯作者：
Xu, Weiwei
中科院分区：
文献类型：
--
作者：
Chen, Min;Zhou, Weibin;Xu, Weiwei
背景：自2019年12月由严重急性呼吸道综合征冠状病毒2型（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）爆发以来，它已影响了6大洲超过200个国家，地区或地区。目前，COVID-19是否对甲状腺功能有影响尚不清楚。本研究的目的是评估COVID-19患者的甲状腺功能。方法：回顾性分析50例实验室确诊的无甲状腺疾病史的COVID-19患者的临床表现、实验室检查结果和胸部CT扫描，这些患者在COVID-19感染期间和恢复后接受了甲状腺功能检查。他们于2020年1月至3月入住中国杭州浙江大学医学院附属第一医院。接受常规体检的健康参与者和同期严重程度相似的非COVID-19肺炎患者被纳入研究作为对照组。分析并比较了COVID-19和对照组之间的甲状腺激素和促甲状腺激素（TSH）水平。结果：56%（28/50）的COVID-19患者TSH低于正常范围。COVID-19患者的TSH和血清总三碘甲状腺原氨酸（TT 3）水平显著低于健康对照组和非COVID-19肺炎患者。COVID-19越严重，TSH和TT 3水平越低，具有统计学意义（p < 0.001）。TSH和TT 3水平下降的程度与疾病的严重程度呈正相关。COVID-19患者的总甲状腺素（TT 4）水平与对照组无显著差异。所有患者均未接受甲状腺激素替代治疗。恢复后，TSH、TT 3、TT 4、游离三碘甲状腺原氨酸（fT 3）和游离甲状腺素（fT 4）水平在COVID-19和对照组之间无显著差异。结论：血清TSH和TT 3水平的变化可能是COVID-19病程的重要表现。
Background:Since the outbreak of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, it has affected >200 countries, areas, or territories in 6 continents. At present, whether COVID-19 has an effect on thyroid function is unclear. The aim of this study was to evaluate thyroid function in patients with COVID-19. Methods:Clinical manifestations, laboratory results, and chest computed tomography scans were retrospectively reviewed for 50 patients with laboratory-confirmed COVID-19 without a history of thyroid disease who underwent thyroid function testing during their course of COVID-19 infection and after recovery. They were admitted to the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, between January and March 2020. Healthy participants who underwent routine physical checkups and non-COVID-19 pneumonia patients with a similar degree of severity during the same period were included in the study as the control group. Thyroid hormone and thyrotropin (TSH) levels were analyzed and compared between the COVID-19 and control groups. Results:TSH lower than the normal range was present in 56% (28/50) of the patients with COVID-19. The levels of TSH and serum total triiodothyronine (TT3) of the patients with COVID-19 were significantly lower than those of the healthy control group and non-COVID-19 pneumonia patients. The more severe the COVID-19, the lower the TSH and TT3 levels were, with statistical significance (p < 0.001). The degree of the decreases in TSH and TT3 levels was positively correlated with the severity of the disease. The total thyroxine (TT4) level of the patients with COVID-19 was not significantly different from the control group. All the patients did not receive thyroid hormone replacement therapy. After recovery, no significant differences in TSH, TT3, TT4, free triiodothyronine (fT3), and free thyroxine (fT4) levels were found between the COVID-19 and control groups. Conclusions:The changes in serum TSH and TT3 levels may be important manifestations of the courses of COVID-19.